Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-12

Study Completion Date

2023-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

NCT03312842

Advanced Cancer

COMPLETED PHASE1

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

NCT03728556

Non-Small Cell Lung Cancer Stage III

COMPLETED PHASE3

A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors

NCT04338724

Advanced Solid Tumor

COMPLETED PHASE1

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

NCT07091305

Limited-stage Small Cell Lung Cancer (LS-SCLC) Chemoradiotherapy Induction Therapy +1 more

ACTIVE_NOT_RECRUITING PHASE2

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

NCT03789604

Non Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a dose-escalation study of Low-dose Radiation in combination with CS1001 in relapsed SCLC patients. Patients are assigned to 3 treatment groups received from 3 Gy to 15Gy, to determine the safety, tolerability and the maximal tolerant dose. Biomarkers and immunological markers are collected and analyzed as well.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low-dose radiation+CS1001

Group Type EXPERIMENTAL

CS1001

Intervention Type DRUG

low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.

Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;

In the dose expansion part, more SCLC patients will be assigned.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CS1001

low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.

Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;

In the dose expansion part, more SCLC patients will be assigned.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and experienced progression since first-line standard platinum containing dual-drug chemotherapy.
2. Patients whose initial diagnosis was limited must undergo radical chest radiotherapy and the time of tumor progression is not less than 3 months from the end of radiotherapy, or cannot receive radical chest radiotherapy due to specific reasons
3. At least one extracranial measurable lesion (RECIST v1.1), and for a lesion that has received radiotherapy, progression of the lesion after radiotherapy must be confirmed.
4. Patients with brain metastases are allowed to receive previous radiotherapy and their condition is stable, but the time to the end of radiotherapy must not be less than 3 months.
5. No radiotherapy contraindications were judged by the radiologist
6. ECOG performance status of 0 or 1.
7. Patients with life expectancy ≥ 3 months.
8. Patients must have adequate organ function.
9. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 6 months after last study drug administration.

Exclusion Criteria

1. Subjects known to have primary CNS tumors or meningeal metastases or unstable CNS metastases.
2. Patients with active autoimmune diseases or history of autoimmune diseases should be excluded.
3. Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.
4. Known history of HIV infection.
5. Subjects with active chronic hepatitis B or active hepatitis C .
6. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.
7. Known history of alcoholism or drugs abuse.
8. Subjects with history of radiation pneumonitis of grade 3 or above, regardless of recovered or not.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No